Cost–Utility Analysis of Radiation Treatment Modalities for Intermediate-Risk Prostate Cancer

Introduction: Variable costs of different radiation treatment modalities have played an important factor in selecting the most appropriate treatment for patients with intermediate-risk prostate cancer. Methods: Analysis using a Markov model was conducted to simulate 20-year disease trajectory, quali...

Full description

Bibliographic Details
Published in:	Current Oncology
Main Authors:	Najlaa Alyamani, Jiheon Song, Sasha van Katwyk, Kednapa Thavorn, Julie Renaud, Alain Haddad, Miller MacPherson, Marc Gaudet
Format:	Article
Language:	English
Published:	MDPI AG 2021-06-01
Subjects:	cost–utility analysis intermediate-risk prostate cancer radiation therapy
Online Access:	https://www.mdpi.com/1718-7729/28/4/219

Similar Items

PSMA PET in Favourable Intermediate-Risk Prostate Cancer? Gold Mine or Money Pit
by: Weiwei Shi, et al.
Published: (2025-08-01)

The cell fates of intermediate cell population in prostate development
by: Xiaoyu Zhang, et al.
Published: (2024-08-01)

Navigating the evolving diagnostic and therapeutic landscape of low- and intermediate-risk prostate cancer
by: Fabio Zattoni, et al.
Published: (2024-10-01)

Human intermediate prostate cancer stem cells contribute to the initiation and development of prostate adenocarcinoma
by: Jie Mu, et al.
Published: (2024-09-01)

The role of endogenous testosterone in relationship with low- and intermediate-risk prostate cancer: a systematic review
by: Antonio Benito Porcaro, et al.
Published: (2024-10-01)

Genomic prostate score and treatment selection in favourable intermediate‐risk prostate cancer
by: Eric Margolis, et al.
Published: (2025-03-01)

Intermediate risk prostate tumors contain lethal subtypes
by: William L. Harryman, et al.
Published: (2025-01-01)

Prognostic Value of the Intermediate-risk Feature in Men with Favorable Intermediate-risk Prostate Cancer: Implications for Active Surveillance
by: Michael V. Sherer, et al.
Published: (2023-04-01)

A modeling study to estimate prostate cancer‐specific mortality on active surveillance for men with favorable intermediate‐risk prostate cancer: Results from the SEARCH cohort
by: Paige K. Kuhlmann, et al.
Published: (2023-05-01)

Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer
by: Benedikt Hoeh, et al.
Published: (2022-03-01)

Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer
by: Hideyasu Tsumura, et al.
Published: (2022-04-01)

Hypofractionated versus conventional fractionation external beam radiotherapy in intermediate and high risk localized prostate cancer
by: Eileen Samuel, et al.
Published: (2024-02-01)

Impact of androgen deprivation therapy in patients with unfavorable intermediate-risk prostate cancer receiving brachytherapy-based dose-escalated radiation therapy
by: Nikhil T. Sebastian, et al.
Published: (2024-09-01)

Influence of Active Surveillance on Gleason Score Upgrade and Prognosis in Low- and Favorable Intermediate-Risk Prostate Cancer
by: Xuanhan Hu, et al.
Published: (2022-10-01)

Effect of Glison index on survival of patients with localized prostate cancer in Samara region
by: R. D. Andreeva, et al.
Published: (2022-05-01)

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis
by: Jiuzhou Chen, et al.
Published: (2023-01-01)

The Evaluation of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Initial Staging in Intermediate-Risk Prostate Cancer Patients: A Retrospective Multicenter Analysis
by: Laura Evangelista, et al.
Published: (2024-12-01)

A Multicenter Phase 2 Study of Ultrahypofractionated Stereotactic Boost After External Beam Radiotherapy in Intermediate-risk Prostate Carcinoma: A Very Long-term Analysis of the CKNO-PRO Trial
by: David Pasquier, et al.
Published: (2023-08-01)

Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial
by: Valentina Borzillo, et al.
Published: (2023-11-01)

Influence of Biopsy Gleason Score on the Risk of Lymph Node Invasion in Patients With Intermediate-Risk Prostate Cancer Undergoing Radical Prostatectomy
by: Mike Wenzel, et al.
Published: (2021-12-01)

Who is discharged to intermediate care facilities? An Italian study in the population of Udine
by: Francesca Valent, et al.
Published: (2020-03-01)

Intermedial ecocriticism in Blindness by Saramago
by: Brunilda Reichmann
Published: (2024-01-01)

Patient preferences for treatment modalities for localised prostate cancer
by: Frederik R. Teunissen, et al.
Published: (2023-03-01)

Long-term results with custom-linked iodine-125 seeds and real-time brachytherapy in low- and intermediate-risk prostate cancer
by: Jose Luis Guinot, et al.
Published: (2022-05-01)

Anatomy of the Prostate Gland: Modalities and Techniques for Its Assessment
by: Gowtham S. Mahadevan, et al.
Published: (2024-05-01)

Comics Intermedial
by: Paul Winkler
Published: (2013-09-01)

Risk Stratification of Prostate Cancer: Preoperatively Assessing Aggressiveness of Favorable and Unfavorable Intermediate-Risk Groups by Advanced Diffusion-Weighted Imaging
by: Hua-Bin Huang, et al.
Published: (2025-09-01)

THE EFFECT OF GIVING INTERMEDIATE AND INTERMEDIATE PLUS GUMBORO VACCINES AT THE AGE OF 21
by: MAAMON AL AMIR, et al.
Published: (2014-10-01)

Music Syncing as Intermedial Translation
by: Michele Rota
Published: (2023-12-01)

Briganti’s 2012 nomogram is an independent predictor of prostate cancer progression in EAU intermediate-risk class: results from 527 patients treated with robotic surgery
by: Antonio Benito Porcaro, et al.
Published: (2024-10-01)

Intermedial performance aesthetics in Patricia Fagundes' A Midsummer Night's Dream
by: Anna Stegh Camati
Published: (2013-12-01)

12 Examination of Listening Comprehension Strategies used by Iranian Upper-intermediate and Intermediate EFL Learners
by: Reza Nemati MOGHADAM, et al.
Published: (2014-12-01)

Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer
by: Giorgio Gandaglia, et al.
Published: (2023-09-01)

Intermediate uveitis
by: Babu B, et al.
Published: (2010-01-01)

A Performative Intermedial Analysis of The Willow Song
by: Giuseppe Pantano
Published: (2026-04-01)

Multi-modal intermediate integrative methods in neuropsychiatric disorders: A review
by: Yanlin Wang, et al.
Published: (2022-01-01)

Stereotactic Body Radiation Therapy for Prostate Cancer: Review of Experience of a Multicenter Phase I/II Dose Escalation Study
by: D. Nathan W. Kim, et al.
Published: (2014-11-01)

High grade intraepithelial neoplasia of prostate is associated with values of prostate specific antigen related parameters intermediate between prostate cancer and normal levels
by: Nermina Obralic, et al.
Published: (2011-11-01)

Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec
by: Jason Hu, et al.
Published: (2022-11-01)

Confirmatory Biopsy Outcomes in Patients with Grade Group 2 Prostate Cancer: Implications for Early Management
by: Riccardo Leni, et al.
Published: (2025-02-01)